Month: September 2021

WM’s ICLM and TUV Unitary Global Payments Systems provide a fully operational and benign model for a functioning Cashless Society worldwide

NEW YORK and ST PETER PORT, Guernsey, Sept. 29, 2021 (GLOBE NEWSWIRE) — To create its Global Clearing System – a digital version of John Maynard Keynes’s proposed “International Clearing Union” – Global Telephony Provider Webtel.mobi (“WM”) also created a Global Unitary Payment System – with two Global Payment Facilities – the ICLM Payments and the TUV Digital Currency Payments (also known as “TUV Payments”).

Both Payment Systems have all the characteristics of Cash Payments and Digital Payments combined, are globally applicable, globally available, require no specialized equipment to function, have multicurrency wallets, enable multicurrency payments with FX Conversions in-wallet, and are equally available to Banked and Unbanked persons.

One of these Payment Systems – the ICLM Payments – is ultra-low cost to use, and the other – TUV Payments – is completely free to use.

These Payment Systems not only facilitate a “Cashless Society”, but have also already introduced a fully operational global Cashless Society system in a benign way. It is benign because this version of a Cashless Society preserves individuals’ privacy, freedom, and choice.

WM’s Payment Systems do not require a Central Bank issued Digital Currency or CBDC to function because WM’s TUV Digital Currency itself is already the equivalent of a Global CBDC.

WM’s Payment Systems – like all its other facilities – are not new. They were functional and operational in 2009, but WM spent nine years testing and perfecting them – and subjecting its system to multiple third-party Due Diligences worldwide – to ensure compliance and robustness before rebuilding its Platform 2 to provide these Facilities in an unrestricted manner internationally.

Access to WM’s services is only available to WM Members because it is a Closed-Loop Members-Only service. However, it is free and instant to join WM as a Member.

WM has one of the safest systems internationally in Security and Anti Money Laundering. WM’s Payment Systems synchronize, into one product, the characteristics of Cash and Digital Money with the ease of use of Cash and the safety of Digital Money. They also have the security of a closed, monitored system and transactions – ensuring robust security and Anti-Money Laundering capacities.

To load WM accounts, Members can transfer funds (”Stored Credit”) into their accounts using any means, and also purchase TUV Digital Currency from WM Agents (“VSMPs”) for cash. The system provides a Unitary and level playing field – and entry into a 21^st Century Digital Economy for all people – whether Banked or Unbanked. It renders even the concepts of “Banked” or “Unbanked” redundant – because the only differentiator is the method used to load funds (“Stored Credit”) onto WM Accounts.

All funds (“Stored Credit”) of WM Members is held in regulated Bank Accounts, so the WM System has permanent 100% liquidity, and all Payment and Settlement Transactions are carried out simultaneously in 1/100^th of a second.

WM’s ICLM Payments and TUV Payments are fully operational, and available to all WM Members on its platform. Examples of some of WM’s ICLM and TUV Payments Systems’ characteristics in comparison to other Payment Systems in the Offline Payments role are as follow:

Once people have joined WM as Members and loaded Stored Credit onto their accounts, they can start using the ICLM Payments of TUV Payments Systems immediately – to make or receive payments. The only requirement is a Smart Phone – or a Pre-Smart Phone (which still comprise 50% of Mobile Phones in use) – and the ITAN Number and Registered Mobile Number of the WM Member they want to pay. That is all.

ITAN Numbers (“Inter-TEL.mobi Account Numbers”) are the unique Account Numbers issued to all WM Members when they join, and the Registered Mobile Number is the member’s Mobile Phone Number.

For Merchants to notify clients they accept ICLM and TUV Payments of WM’s unique Global Account Numbering system, they simply need to display this sign, and indicate they accept payment in only one currency, only some currencies or in all currencies.

As all WM Members can execute in-wallet Currency Conversions or Currency Swaps within WM, it makes no difference whether only one currency or all currencies are accepted. This is because all Members can convert before paying or after receiving payments. Examples of the Merchant notifications for accepting ICLM and TUV Payments are as follow:

Resources:

Media Contact:
Nick Lambert: wm@thoburns.com

Video on WM’s Regulatory Compliance:
https://youtu.be/u522lVsGIJI

Video on The Capacities of the WM System:
https://youtu.be/XYBrCikUhn8

Research Reports on the Capacities of the WM System:
https://tinyurl.com/TUVresearch

WM’s urls:
https://webtel.mobi/pc (Tablets / Laptops / Desktops)
https://webtel.mobi (Smart Phones)
https://webtel.mobi/wap (Pre-Smart Mobile Phones)

Philogen Provides Corporate Update

• Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trials
• Use of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical trials
• Early evidence of potent activity of Fibromun in combination with Standard of Care in last line patients with Glioblastoma and Soft Tissue Sarcoma
• Clinical experience with OncoFAP confirms preclinical results, recently published in Proceedings of the National Academy of Sciences U.S.A.
• Positive net financial position of €96.077M compared to €104.668M at 31 March 2021 (€44.238M at 31 December 2020)
• Philogen’s management team will hold a Webinar to discuss the news on Wednesday 29^th of September 2021 at 12:00 ET / 17:00 BST / 18:00 CEST (Please find the link to this Webinar here)

Siena (Italy), 29 September 2021 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics announces its Interim Results for the six month period ended 30^th June 2021 and provides an update regarding recent corporate developments.

Dario Neri, CEO of Philogen, commented on the results for the year and the evolution of the business:

“ Following our recent listing, I am delighted to report that Philogen has made significant progress both in our clinical and pre-clinical stage pipeline, showing curative potential in difficult to treat preclinical models of cancer.

Development for pivotal clinical trials is progressing on track. We expect to complete patient enrollment in the European Phase III clinical trial of Nidlegy™ in melanoma by mid-2022. With respect to the two European clinical trials of Fibromun in newly diagnosed and second recurrence sarcoma, completion of recruitment of the respective patients is expected by the end of 2023.

Clinical trials in patients with last line Glioblastoma or with last line Soft Tissue Sarcoma, for which objective responses are very rarely observed using Standard of Care drugs, are showing signs of potent clinical activity when Fibromun is added to the treatment.

I am also pleased to see that we are making progress in the clinical development of small molecules targeted therapeutics. OncoFAP, our proprietary targeting platform directed against Fibroblast Activation Protein, is revealing a significant ability to selectively localize both primary and heavily disseminated tumors in patients. This Nuclear Medicine validation paves the way for the implementation of innovative therapeutic strategies.

Philogen remains committed to the development of pharmaceutical products with game changing potential for difficult to treat conditions and is well capitalized to aggressively perform its industrial plan.“

MAIN EVENTS FOR THE FIRST HALF 2021 AND RECENT HIGHLIGHTS

Proprietary products

• Nidlegy™ is a pharmaceutical product, proprietary to Philogen, consisting of two active ingredients, L19-IL2 and L19-TNF. The L19 antibody is specific for the B domain of Fibronectin, a protein expressed in tumors (and other diseases), but absent in most healthy tissues. Interleukin 2 (IL2) and Tumor Necrosis Factor (TNF) are inflammatory cytokines with anti-tumor activities.
  • Phase III studies in Stage IIIB/C melanoma – New centers opened with the goal of accelerating patient enrollment in both the U.S. and Europe;
  • European Phase III study in Stage III B/C melanoma – enrolled 168 patients as of June 30, 2021. In addition, after the close of the 2021 financial year and up to the present date, additional 13 patients have been recruited after the close of the year, reaching a total number of 181 patients;
  • U.S. Phase III study in Stage III B/C melanoma – signed contract with a Contract Research Organization to open up to 38 clinical centers to add to ongoing study;
  • US Phase II study in stage IV melanoma – revised clinical protocol submission to US Food and Drug Administration is expected;
  • European Phase II study in non-melanoma skin cancers – Promising clinical data at ten months post-treatment on Nidlegy™ in patients with basal cell carcinoma. The clinical trial features the participation of clinical centers in Germany, Switzerland and Poland. Additional countries are planned to be involved in Phase II studies;
• Fibromun is a pharmaceutical product, proprietary to Philogen, consisting of the L19 antibody fused to TNF.
  • Soft tissue sarcoma – Opening of new clinical centres in Germany, Spain, Italy, Poland and the United States, with the aim of accelerating enrolment in the three ongoing clinical trials (two European and one American);
  • European Phase II study in soft tissue sarcoma with at least two recurrences (i.e., ≥ third line of treatment) – Completed patient enrollment in the Run-in portion of the study. The objective of this phase is to confirm drug tolerability and to monitor early signs of efficacy in a limited number of patients. In this setting, Fibromun is administered in combination with Dacarbazine. An objective response has been observed. The historical objective response rate for this population is 4.3% (Garcia-del-Muro et al., J Clin Oncol 2011, 29,2528). The randomized phase is planned to begin, subject to approval by the Data and Safety Monitoring Board;
  • Glioblastoma (i.e., grade IV glioma) – Completed a Parallel Scientific Advice (PSA) with the European Medicines Agency and the U.S. Food and Drug Administration in June 2021. The development plan for the treatment of glioblastoma and the proposed strategy for marketing authorisation have been discussed and agreed with the relevant authorities. Philogen will follow the recommendations that were provided during the PSA;
  • Phase II study in Grade III-IV wildtype IDH glioma at first relapse/recurrence – Promising interim survival benefits observed in the European Phase I/II study, in which Fibromun is being studied as monotherapy. Data on Progression Free Survival at six months from the start of treatment are being completed, while data on Overall Survival will be consolidated by the end of 2021;
  • Phase I/II study in glioblastoma at first relapse/recurrence – monitoring of Safety, presence of Objective Responses and Progression Free Survival in patients treated during the dose escalation portion (i.e., Phase I of the study). The first patient in the trial, treated with Fibromun plus Lomustine, exhibited a tumor shrinkage of 74% at 18 weeks and of 92% at 24 weeks. The patient (and the ones who have been treated after him, for whom follow-up time is still insufficient) will continue to be monitored at regular intervals. The historical objective response rate for this patient population upon Lomustine treatment is 4.3% and responses of this magnitude and duration are virtually never observed (Wick et al., J Clin Oncol 2010, 28,1168).
• OncoFAP is a small organic molecule, proprietary to Philogen group, with affinity for Fibroblast Activation Protein (FAP). The product has the ability to selectively localize in a variety of metastatic solid tumors.
  • Excellent targeting capabilities of OncoFAP in patients with various tumor types. Clinicians at the Department of Nuclear Medicine of the University Hospital Münster have used OncoFAP radiolabeled with gallium-68 (OncoFAP-68Ga) to detect neoplastic lesions of both primary and metastatic origin. Of note is the intense uptake in the tumor and the low absorption in healthy organs (including kidneys) after only 1h after intravenous administration of the drug. Thus, imaging results in cancer patients confirmed the excellent properties of OncoFAP observed in preclinical models, which have recently been published by the Philogen group in the Proceedings of the National Academy of Sciences U.S.A.;
  • Several international Phase I/II clinical trials are currently being designed, with the aim of studying OncoFAP-68Ga (diagnostic agent) and OncoFAP-177Lu (diagnostic and therapeutic agent) in a larger number of patients with different types of cancer. These studies will provide an indication of which tumor(s) will be the focus of clinical trials. These studies are expected to begin in 2022.

Licensed products

• Continue partnerships on Dodekin (Confidential Partner) and Dekavil (Pfizer);
• ABBV-022 is a product generated and out-licensed by Philogen. The drug consists of the cytokine interleukin 22 fused to a monoclonal antibody;
  • Start of a phase I clinical trial for the treatment of ulcerative colitis

GMP

• The structural work on the second GMP production plant, located at the Philogen site in Rosia (Siena), was completed on schedule in line with the business plan. The new plant has been designed to meet the highest regulatory standards for the production of therapeutic protein-based drugs and will be used for the production of commercial pharmaceuticals and clinical trial drug products. The installation and validation of the process machines at the new GMP site is expected to be completed in the first quarter of 2022, following which authorization from the Italian competent authority (AIFA) will be sought for the production and marketing of the drugs. It should be noted that the Company already has a production site in Montarioso that is authorized by AIFA solely for the production of experimental drugs for clinical trials;

Financial Highlights

• Revenues from contracts with customers amounting to €1.548M (€2.308M at 30 June 2020)
• EBITDA of negative €8.107M (negative €5.646M at 30 June 2020)
• EBIT of negative €8.860M (negative €6.352M at 30 June 2020)
• Net loss of €8.653M (net loss of €8.424M at 30 June 2020)
• Positive net financial position of €96.077M compared to €104.668M at 31 March 2021 (€44.238M at 31 December 2020)

Philogen Group Description

Philogen is an Italian-Swiss company active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. The Group mainly discovers and develops targeted anticancer drugs, exploiting high-affinity ligands for tumour markers (also called tumour antigens). These ligands – human monoclonal antibodies or small organic molecules – are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies.

The Group’s main therapeutic strategy for the treatment of these diseases is represented by the so-called tumor targeting. This approach is based on the use of ligands capable of selectively delivering very potent therapeutic active ingredients (such as pro-inflammatory cytokines) to the tumor mass, sparing healthy tissues. Over the years, Philogen has mainly developed monoclonal antibody-based ligands that are specific for antigens expressed in tumor-associated blood vessels, but not expressed in blood vessels associated with healthy tissues. These antigens are usually more abundant and more stable than those expressed directly on the surface of tumor cells. This approach, so called vascular targeting, is used for most of the projects pursued by the Group.

The Group’s objective is to generate, develop and market innovative products for the treatment of diseases for which medical science has not yet identified satisfactory therapies. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights.

Although the Group’s drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases.

FOR MORE INFORMATION:

Philogen – Investor Relations

IR@philogen.com – Emanuele Puca | Investor Relations

Consilium Strategic Communications contacts

Mary-Jane Elliott, Davide Salvi

Philogen@consilium-comms.com

The Distinguished Gentleman’s Drive attracts thousands of vintage automotive enthusiasts in its first-ever global charity drive, raising $200,000 for men’s mental health and prostate cancer research. DGD 2022 date is set for Sept. 26, 2021.

Two Dapper Gents Driving in DGD Lisbon, 2021

Two Dapper Gents Driving in DGD Lisbon, 2021

SYDNEY, Sept. 29, 2021 (GLOBE NEWSWIRE) — On Sunday, Sept. 26, 2021, thousands of dapper drivers took part in the world’s largest and most stylish vintage automotive event. The first event of its kind, The Distinguished Gentleman’s Drive’s inaugural event focused on establishing flagship drives around the world to raise awareness and capture content within local communities. With the premise that all drivers must be behind the wheel of a pre-1980s vehicle and be dressed to suit, the event successfully took place in over 145 cities and 55 countries around the world, connecting 4,000 drivers to its causes of prostate cancer and men’s mental health.

The event raised over $200,000 USD for its charity partner Movember, which is the world’s leading global organization focused solely on men’s health. The funds raised through The Distinguished Gentleman’s Drive will be directed toward prostate cancer research and men’s mental health programs.

Founder of The Distinguished Gentleman’s Drive, Mark Hawwa, reflects on the inaugural event.

“It’s been surreal to experience the success of The Distinguished Gentleman’s Drive within its first year. What we were able to achieve, along with the support from all our volunteers and participants, is exciting. We surpassed every expectation for our inaugural year, raising more than what The Distinguished Gentleman’s Ride did in its first year as a fundraising event. We’re proud to be able to bring classic automotive enthusiasts together and continue building upon our passion for men’s health and motoring.”

Every drive around the world features a unique selection of cars and drivers, encouraging folks to get out on the open road to celebrate the life and connection that is made through pre-’80s machines. Drivers’ dapper style and gentlemanly conduct perfectly complement classic cars with raising funds and awareness for men’s health.

Click here for DGD 2021 Global Media Photography

The Distinguished Gentleman’s Drive will return on Sunday, Sept. 25, 2022. Anyone looking to take part in their local drive or start one of their own, please subscribe at www.gentlemansdrive.com.

For more information, contact: Ramsey Sayed | ramsey@gentlemansdrive.com.

About The Distinguished Gentleman’s Ride

The Distinguished Gentleman’s Ride unites classic and vintage style motorcycle riders all over the world to raise funds and awareness for prostate cancer research and men’s mental health. The Distinguished Gentleman’s Ride was founded in Sydney, Australia, in 2012 by Mark Hawwa. Since then, the event has raised over $31.5 million USD, connecting the global motorcycling community to their health. Visit www.gentlemansride.com for more.

Related Files

DGD21_PR.pdf

Related Images

Image 1: Two Dapper Gents Driving in DGD Lisbon, 2021

Photograph from The Distinguished Gentleman’s Drive 2021 in Lisbon, Portugal. Photographed by Manuel Portugal Photography.

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Two Dapper Gents Driving in DGD Lisbon, 2021

“Conscience is like a beautiful and fragrant flower. When in blossom, the fragrance will enliven the world and be smelled by all.” ~ Dr. Hong, Tao-Tze

Tai Ji Men Martial Arts Family

Tai Ji Men is a spiritual organization that practices qigong and martial arts and aims to improve global citizens’ physical, mental, and spiritual health.

LOS ANGELES, Sept. 28, 2021 (GLOBE NEWSWIRE) — Tai Ji Men Qigong Academy in Los Angeles celebrated its 21st birthday on September 26, 2021. Because the Delta variant of COVID-19 is rapidly spreading, the anniversary celebration was conducted virtually, and everyone was invited to participate in the wonderful event by watching it online.

For the past 21 years, under the leadership of Dr. Hong, Tao-Tze, the Academy has held various life wisdom and health symposiums as well as cultural exchange activities, and it has engaged in numerous international events to promote a culture of conscience, love, and peace, with the goal of improving global citizens’ physical, mental, and spiritual health. In recent years, Tai Ji Men has been promoting the “Movement of An Era of Conscience” and the “International Day of Conscience” to awaken the conscience in the people of the world. During the SARS outbreak in 2002 and during the COVID-19 pandemic, which started in the end of 2019, Tai Ji Men produced videos featuring epidemic prevention guidelines, including Three Don’ts, Five Do’s, and Six Tips as well as a trilogy on COVID-19 prevention measures: Antiviral Combat, The War Against Virus, and Anti Pandemic Battle. It has been sharing these videos with global citizens, hoping that everyone will stay safe, healthy, and happy and that the pandemic will end soon.

Many community leaders offered certificates of recognition or delivered congratulatory video messages in honor of the Academy’s 21st anniversary, acknowledging the contributions of the leader and members of Tai Ji Men for the community, the United States, and the world as Tai Ji Men has been widely promoting the culture of qigong and martial arts as well as a culture of love, peace, and conscience.

U.S. Congresswoman Young Kim said, “For 21 years, Tai Ji Men Qigong Academy has served as a home and a center for self-improvement for many of our community members through martial arts and qigong. I want to thank you for fostering our future leaders, physically, mentally and spiritually.”

California State Senator Josh Newman presented a California Senate Certificate of Recognition to the Academy and stated in his video message, “Despite the pandemic, your academy has continued to thrive, serving as a vital pillar to our community by reaffirming the spirit of universal brotherhood, etiquette, and conscience during a time when such an example is vitally needed across our state and across our country as a whole.”

California Assemblyman Phillip Chen said, “I really appreciate all they’ve done for our community and also for the state of California,” commending Tai Ji Men for improving people’s wellness and health through martial arts and qigong. He also honored Tai Ji Men Qigong Academy and Dr. Hong, Tao-Tze with a California Legislature Assembly Resolution respectively in recognition of their contributions.

Diamond Bar City Council Member Andrew Chou said that the pandemic has been hard on everybody and that Tai Ji Men’s work is very important in maintaining people’s physical and mental health. “I understand that throughout the pandemic, you have been actively hosting virtual events both locally and internationally. And also throughout social media, you have continued to share preventive measures to overcome anxiety and stress caused by the pandemic. So thank you again for all you do and congratulations on your 21st anniversary,” he added.

Walnut Valley Unified School District Board President Layla Abou-Taleb said, “I want to congratulate the Tai Ji Men Qigong Academy for 21 years of service to the community. You play an important role and we really, truly appreciate it and wishing you a better year, this coming year for all our students and our community.”

In addition to the aforementioned video messages and certificates of recognition, Tai Ji Men also received certificates of recognition from other leaders and entities, including California State Senator Connie M. Leyva, Mayor Eric Ching of the City of Walnut, Arcadia Mayor Sho Tay, and the City Council of Montclair.

Jason Wang, a Tai Ji Men member who immigrated to the U.S. with his parents 20 years ago and grew up with the Tai Ji Men Qigong Academy in Los Angeles, had a lot to say about the Academy’s 21st birthday. Since he is 6-foot-3 and in good shape, it’s difficult to imagine that he had serious health issues as a child and had to go to the doctor frequently for asthma and allergies. He said, “There was one time I was jumping on a bed with my cousin, and I ended up having to go to the hospital because of the asthma attack.” “After joining Tai Ji Men, my health has improved tremendously. I no longer was getting any asthma attack,” he said. Last year, he was blessed with a new baby. He was already very busy with his work, and the new addition to his family made him even busier. He gained a better understanding of the reminder from his Shifu (master) at Tai Ji Men: “Those who use their time wisely can find time to accomplish a lot.” He has learned to manage his time well so that he can balance life and work. He also learned to think positively. He shared a piece of advice from his master by saying, “You can live a day happy, or you can live a day sad or angry. So why would you want to live your day in anger or in sadness?” Jason said that practicing Tai Ji Men Qigong helps him replenish his energy, and he expressed his gratitude for Dr. Hong: “Shifu has taught me a lot. So from his teaching, I’m able to utilize that in my personal life and my work life. And he has just helped me become a better person.”

Munni Irone, founder of the Art 4 Peace Awards, met Tai Ji Men members at an international conference many years ago and decided to join to practice qigong and cultivate her heart. She shared some of the benefits of practicing Tai Ji Men Qigong: “It kept me very centered. It kept me from having stress. I work long hours without any stress because it allows me to do that. Tai Ji Men Qigong has numerous different benefits, not only just health benefits. There is a social benefit, emotional, and spiritual benefit.” She continued by saying, “Your skin is better. You have more energy. You are also very successful in business because people trust someone that has good energy. So you create your Qi; you create your energy to be successful.” She said that she used to suffer from back problems, but that she is now in much better shape. She said, “Shifu is a very kind and very influential and compassionate human being, who is also helpful in creating this beautiful family of love and peace.” “In Tai Ji Men you can be in any faith and religion. It really doesn’t matter because this is something on a different level for mental, spiritual, and physical spirituality, so I’m very blessed to be part of this beautiful family. I’m very thankful for Dr. Hong, for creating this wonderful family where you can center so many people,” she added.

Tai Ji Men Qigong has benefited not only many adults but also children. A group of children who practice Tai Ji Men Qigong revealed some of the most important lessons they’ve learned at Tai Ji Men, and it’s clear from their sharing that the concepts of love, peace, and conscience have been imprinted in their hearts to extend their horizons in life. Nathan, 12, said, “Shifu taught me to be kind, nice, and happy.” Mayra, 10, said, “Shifu has taught me to always love myself and follow my conscience and do the right thing.” Avery, 10, said, “I love Tai Ji Men because it taught me that if I don’t know what’s right or wrong, I follow my conscience. It also taught me qigong to bring peace to the world and to love myself and others, no matter what.” Cameron, 8, said, “Shifu told me that practicing qigong will help me calm myself down, and he also told me that love and peace can make the world a better place.” Aaron, 11, said, “Shifu taught me qigong and life lessons that would improve my life and my quality of life, that makes me not depressed and not too emotional at hard times.” Rylan, 9, said, “Shifu taught me qigong to be brave and to know what is right and what is wrong.” Leon, 10, said, “Shifu taught me to do qigong to improve my health, and he also taught me to control my anger.”

Tai Ji Men invites everyone to read the uplifting stories of Tai Ji Men members from all walks of life on its website at www.taijimen.org, to replenish positive energy. Tai Ji Men encourages people to listen to their conscience, think positively, do good deeds, and collaborate to bring the pandemic to an end as soon as possible!

Tai Ji Men Qigong Academy: Tai Ji Men is an ancient menpai (similar to school) of qigong, martial arts, and self-cultivation. It has carried forward the wisdom of Daoist philosophy, one of the highest philosophies of humankind. It is an international nonprofit cultural organization. Its contemporary zhang-men-ren (grandmaster), Dr. Hong, Tao-Tze established the Tai Ji Men Qigong Academy in 1966, and since then it has grown to 15 academies worldwide. In 2016, it commemorated its 50th anniversary, a major milestone in its history, with big celebrations and spectacular cultural performances in Los Angeles, San Francisco, and Taiwan.

Dr. Hong teaches his dizi (similar to disciples) methods to achieve physical, mental, and spiritual balance, and tens of thousands of families have benefited from his teaching. At Tai Ji Men, martial arts and wisdom have been passed down from the shifu (master) to his dizi. Through this time-honored tradition, the shifu and dizi promote the Tai Ji Men culture and martial arts around the world while embodying what is true, good, and beautiful as well as spreading the ideas of conscience, love, and peace. Over the past half-century, the shifu and dizi have self-funded trips to over 300 cities in 101 nations to conduct more than 3,000 cultural performances and exchanges and have been recognized as “International Ambassadors of Peace and Goodwill.”

Media Contact:
Lily Chen
Representative
info@taijimenla.org
626-202-5268

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ff274db-6012-4b58-bf66-64d620ced1fc